ClinVar Miner

Submissions for variant NM_000771.3(CYP2C9):c.1075A>C (p.Ile359Leu) (rs1057910)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 17
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
PharmGKB RCV000211403 SCV000268147 drug response acenocoumarol response - Dosage, Toxicity/ADR 2016-07-11 reviewed by expert panel curation PharmGKB Level of Evidence 2A: Annotation for a variant-drug combination that qualifies for level 2B where the variant is within a VIP (Very Important Pharmacogene) as defined by PharmGKB. The variants in level 2A are in known pharmacogenes, so functional significance is more likely.
PharmGKB RCV000211164 SCV000268153 drug response celecoxib response - Dosage 2016-07-11 reviewed by expert panel curation PharmGKB Level of Evidence 2A: Annotation for a variant-drug combination that qualifies for level 2B where the variant is within a VIP (Very Important Pharmacogene) as defined by PharmGKB. The variants in level 2A are in known pharmacogenes, so functional significance is more likely.
PharmGKB RCV000211251 SCV000268154 drug response Antiinflammatory agents, non-steroids response - Toxicity/ADR 2016-07-11 reviewed by expert panel curation PharmGKB Level of Evidence 2A: Annotation for a variant-drug combination that qualifies for level 2B where the variant is within a VIP (Very Important Pharmacogene) as defined by PharmGKB. The variants in level 2A are in known pharmacogenes, so functional significance is more likely.
PharmGKB RCV000211339 SCV000268155 drug response celecoxib response - Toxicity/ADR 2016-07-11 reviewed by expert panel curation PharmGKB Level of Evidence 2A: Annotation for a variant-drug combination that qualifies for level 2B where the variant is within a VIP (Very Important Pharmacogene) as defined by PharmGKB. The variants in level 2A are in known pharmacogenes, so functional significance is more likely.
PharmGKB RCV000211161 SCV000268156 drug response diclofenac response - Toxicity/ADR 2016-07-11 reviewed by expert panel curation PharmGKB Level of Evidence 2A: Annotation for a variant-drug combination that qualifies for level 2B where the variant is within a VIP (Very Important Pharmacogene) as defined by PharmGKB. The variants in level 2A are in known pharmacogenes, so functional significance is more likely.
PharmGKB RCV000660766 SCV000783005 drug response warfarin response - Dosage 2018-04-06 reviewed by expert panel curation PharmGKB Level of Evidence 1A: Annotation for a variant-drug combination in a CPIC or medical society-endorsed PGx guideline, or implemented at a PGRN site or in another major health system.
PharmGKB RCV000660767 SCV000783006 drug response acenocoumarol response - Toxicity/ADR 2018-04-06 reviewed by expert panel curation PharmGKB Level of Evidence 2A: Annotation for a variant-drug combination that qualifies for level 2B where the variant is within a VIP (Very Important Pharmacogene) as defined by PharmGKB. The variants in level 2A are in known pharmacogenes, so functional significance is more likely.
PharmGKB RCV000660768 SCV000783007 drug response warfarin response - Toxicity/ADR 2018-04-06 reviewed by expert panel curation PharmGKB Level of Evidence 2A: Annotation for a variant-drug combination that qualifies for level 2B where the variant is within a VIP (Very Important Pharmacogene) as defined by PharmGKB. The variants in level 2A are in known pharmacogenes, so functional significance is more likely.
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000339502 SCV000331714 other not provided 2015-07-10 criteria provided, single submitter clinical testing
Medical Genetics Summaries RCV000787930 SCV000926949 drug response Flurbiprofen response 2019-02-11 criteria provided, single submitter curation The dose of flurbiprofen should be reduced in individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) to avoid abnormally high plasma levels due to reduced metabolic clearance.
Medical Genetics Summaries RCV000788094 SCV000927092 drug response Lesinurad response 2019-02-11 criteria provided, single submitter curation Lesinurad should be used with caution in individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) because of increased exposure and an increased risk of side effects.
Medical Genetics Summaries RCV000788100 SCV000927098 drug response Piroxicam response 2019-02-11 criteria provided, single submitter curation Individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) have reduced clearance of piroxicam. Because the standard recommended dose of piroxicam may cause abnormally high plasma levels, a dose reduction should be considered for these individuals.
OMIM RCV000008916 SCV000029126 drug response Tolbutamide response 2010-12-30 no assertion criteria provided literature only
OMIM RCV000008917 SCV000029127 drug response Warfarin response 2012-06-15 no assertion criteria provided literature only
OMIM RCV000008918 SCV000029128 drug response Phenytoin response 2012-06-15 no assertion criteria provided literature only
OMIM RCV000008919 SCV000029129 drug response Glipizide response 2012-06-15 no assertion criteria provided literature only
Pharmacogenomics Lab,Chungbuk National University RCV000008917 SCV000889937 drug response Warfarin response 2010-08-31 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.